ThermoGenesis wins NIH grant for cell-processing disposable product

By The Science Advisory Board staff writers

September 14, 2021 -- ThermoGenesis has received a $250,000 Small Business Innovation Research (SBIR) phase I grant from the U.S. National Institutes of Health (NIH) to develop and test the company's single-use sterile cell-processing disposable product.

There are two specific aims of the NIH's grant, according to ThermoGenesis. The first aim is to prototype and manufacture in small quantities an enhanced X-Series cartridge. The second aim is to validate and optimize the performance of all steps of gene-engineered autologous cell therapy (GEAC) manufacturing in a single cartridge.

The company said it intends to apply for a phase II SBIR grant to design and validate the Quintessence instrument that will fully automate the specific workflow.

ThermoGenesis launches cell processing system for cell therapies
ThermoGenesis has completed the development process for its PXP-Lavare system for automated cell processing. The company has submitted a letter to file...
ThermoGenesis launches new cell processing products
ThermoGenesis has started distribution of the X-Series cell processing platform under the Corning Life Sciences brand, as part of an exclusive global...
ThermoGenesis to develop COVID-19 therapeutics
ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics...

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter